Group One Trading’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.72M | Buy |
8,700
+4,450
| +105% | +$858K | ﹤0.01% | 2210 |
|
|
2025
Q4 | $781K | Sell |
4,250
-6,050
| -59% | -$1.06M | ﹤0.01% | 3115 |
|
|
2025
Q3 | $1.58M | Buy |
10,300
+4,150
| +67% | +$628K | ﹤0.01% | 2553 |
|
|
2025
Q2 | $860K | Buy |
6,150
+1,900
| +45% | +$266K | ﹤0.01% | 2906 |
|
|
2025
Q1 | $625K | Buy |
4,250
+1,000
| +31% | +$145K | ﹤0.01% | 2875 |
|
|
2024
Q4 | $426K | Buy |
3,250
+2,000
| +160% | +$280K | ﹤0.01% | 3312 |
|
|
2024
Q3 | $195K | Sell |
1,250
-4,300
| -77% | -$694K | ﹤0.01% | 3634 |
|
|
2024
Q2 | $866K | Buy |
5,550
+3,450
| +164% | +$519K | ﹤0.01% | 2114 |
|
|
2024
Q1 | $285K | Sell |
2,100
-26,950
| -93% | -$3.57M | ﹤0.01% | 3256 |
|
|
2023
Q4 | $3.91M | Sell |
29,050
-15,500
| -35% | -$2.01M | 0.01% | 1328 |
|
|
2023
Q3 | $6.03M | Buy |
44,550
+3,500
| +9% | +$478K | 0.02% | 823 |
|
|
2023
Q2 | $5.88M | Buy |
41,050
+19,300
| +89% | +$2.84M | 0.02% | 840 |
|
|
2023
Q1 | $3.02M | Sell |
21,750
-66,550
| -75% | -$8.95M | 0.01% | 1196 |
|
|
2022
Q4 | $12M | Buy |
88,300
+27,150
| +44% | +$3.4M | 0.03% | 630 |
|
|
2022
Q3 | $6.71M | Sell |
61,150
-4,400
| -7% | -$558K | 0.01% | 960 |
|
|
2022
Q2 | $8.66M | Sell |
65,550
-18,400
| -22% | -$2.41M | 0.01% | 943 |
|
|
2022
Q1 | $11.1M | Sell |
83,950
-67,350
| -45% | -$8.08M | 0.01% | 925 |
|
|
2021
Q4 | $17.6M | Buy |
151,300
+2,350
| +2% | +$277K | 0.01% | 745 |
|
|
2021
Q3 | $17.9M | Sell |
148,950
-13,750
| -8% | -$1.6M | 0.02% | 677 |
|
|
2021
Q2 | $19.5M | Sell |
162,700
-40,800
| -20% | -$4.48M | 0.02% | 645 |
|
|
2021
Q1 | $20.2M | Buy |
203,500
+33,650
| +20% | +$3.38M | 0.03% | 533 |
|
|
2020
Q4 | $17M | Buy |
169,850
+49,450
| +41% | +$5.24M | 0.03% | 525 |
|
|
2020
Q3 | $13.2M | Buy |
120,400
+43,800
| +57% | +$4.87M | 0.04% | 410 |
|
|
2020
Q2 | $8.1M | Buy |
76,600
+30,750
| +67% | +$3.18M | 0.04% | 546 |
|
|
2020
Q1 | $4.09M | Buy |
45,850
+13,450
| +42% | +$1.27M | 0.03% | 639 |
|
|
2019
Q4 | $3.23M | Sell |
32,400
-5,100
| -14% | -$480K | 0.02% | 944 |
|
|
2019
Q3 | $3.34M | Sell |
37,500
-3,150
| -8% | -$273K | 0.03% | 831 |
|
|
2019
Q2 | $3.36M | Buy |
40,650
+9,050
| +29% | +$710K | 0.03% | 747 |
|
|
2019
Q1 | $2.56M | Sell |
31,600
-11,900
| -27% | -$938K | 0.03% | 767 |
|
|
2018
Q4 | $3.3M | Buy |
43,500
+24,550
| +130% | +$1.92M | 0.03% | 710 |
|
|
2018
Q3 | $1.5M | Buy |
18,950
+13,350
| +238% | +$1.01M | 0.01% | 1379 |
|
|
2018
Q2 | $393K | Sell |
5,600
-12,500
| -69% | -$899K | ﹤0.01% | 2501 |
|
|
2018
Q1 | $1.27M | Sell |
18,100
-54,000
| -75% | -$3.74M | 0.01% | 1329 |
|
|
2017
Q4 | $5M | Sell |
72,100
-108,550
| -60% | -$7.32M | 0.04% | 637 |
|
|
2017
Q3 | $12.2M | Buy |
180,650
+10,500
| +6% | +$663K | 0.11% | 203 |
|
|
2017
Q2 | $11.6M | Sell |
170,150
-24,550
| -13% | -$1.6M | 0.12% | 184 |
|
|
2017
Q1 | $12.1M | Buy |
194,700
+56,700
| +41% | +$3.3M | 0.14% | 152 |
|
|
2016
Q4 | $7.54M | Buy |
+138,000
| New | +$7.84M | 0.07% | 297 |
|
Other funds holding AZN
IA
VCM
VAM
Group One Trading's AZN Position: Q3 2025 in Review
Group One Trading sold out of AstraZeneca (AZN) in Q3 2025, closing a stake of 16,406 shares — an estimated $2.48M sold.
Group One Trading first reported a position in AZN in Q2 2014 and held it in 21 quarters. The position peaked at $24.9M in Q3 2014. 1,287 funds tracked by Wall St. Rank hold AZN as of Q3 2025.
- Group One Trading reported no remaining AstraZeneca position as of Q3 2025 after selling out during the quarter.
- Group One Trading sold 16,406 AstraZeneca shares in Q3 2025, an estimated $2.48M.
- Group One Trading first reported a position in AstraZeneca in Q2 2014 and held it in 21 quarters.
- Group One Trading's AstraZeneca position peaked at $24.9M in Q3 2014.
- 1,287 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2025.
Based on Group One Trading's 13F filing for Q3 2025, filed 12 Nov 2025.